Cargando…
Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine — A Novel Immunotherapeutic Strategy
BACKGROUND: The development of a safe and effective AD vaccine requires a delicate balance between providing an adequate anti-Aβ antibody response sufficient to provide therapeutic benefit, while eliminating an adverse T cell-mediated proinflammatory autoimmune response. To achieve this goal we have...
Autores principales: | Movsesyan, Nina, Ghochikyan, Anahit, Mkrtichyan, Mikayel, Petrushina, Irina, Davtyan, Hayk, Olkhanud, Purevdorj B., Head, Elizabeth, Biragyn, Arya, Cribbs, David H., Agadjanyan, Michael G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2358976/ https://www.ncbi.nlm.nih.gov/pubmed/18461171 http://dx.doi.org/10.1371/journal.pone.0002124 |
Ejemplares similares
-
Mannan-Abeta(28 )conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice
por: Petrushina, Irina, et al.
Publicado: (2008) -
The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease
por: Davtyan, Hayk, et al.
Publicado: (2011) -
Alzheimer’s disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules
por: Davtyan, Hayk, et al.
Publicado: (2016) -
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
por: Agadjanyan, Michael G., et al.
Publicado: (2017) -
Olfactory dysfunction in the 3xTg-AD model of Alzheimer’s disease
por: Mitrano, Darlene A., et al.
Publicado: (2021)